Drug Profile
SPR 965
Alternative Names: SPR-965Latest Information Update: 02 Jun 2022
Price :
$50
*
At a glance
- Originator Sphaera Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Multiple myeloma
Most Recent Events
- 08 Apr 2022 SPR 965 is still in preclinical phase for Solid tumours in Singapore
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 28 May 2019 No recent reports of development identified for preclinical development in Multiple-myeloma in Singapore (PO)